Merck Presents Positive Phase 2 Data for Enpatoran Demonstrating Reduction in Disease Activity in Patients with Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) with Active L ...

Although systemic lupus erythematosus cannot be cured, there are a number of drugs available to help manage this chronic ...

Cohort A focused on patients with CLE or SLE with active lupus rash ... often including fatigue, joint pain, rashes and organ involvement. Lupus disproportionately impacts women and people of ...

Lupus Awareness Month shines a spotlight on a disease that affects millions worldwide yet remains widely misunderstood. Lupus ...

WILLOW is a global, multicenter, randomized, placebo-controlled Phase 2 study evaluating three doses of enpatoran taken twice daily (25 mg, 50 mg and 100 mg) versus placebo plus standard of care (SoC) ...

Cohort analyses from the WILLOW study reveal clear proof of concept in patients with CLE and SLE with active lupus rash, showing clinically meaningful ...

Distal interphalangeal joint involvement is common ... into Caring for Adult Patients with JIA and Childhood-Onset SLE. Presented at The Congress of Clinical Rheumatology East; May 1-4, 2025 ...

Genetics, environmental triggers like sunlight and infections, stress, and hormonal fluctuations all play roles in its onset and progression. Its symptoms can resemble those of arthritis, thyroid ...

Background: Joint involvement occurs in most patients with systemic lupus erythematosus (SLE), and severe lupus arthritis is often refractory to conventional treatments. Anakinra is used in the ...

Riya began to get "off" feelings at the age of 22. Her symptoms were subtle: body aches, periodic low-grade fevers, fatigue ...